FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128421277> ?p ?o ?g. }

• W2128421277 endingPage "1219" @default.
• W2128421277 startingPage "1214" @default.
• W2128421277 abstract "The proportion of cardiac transplant recipients with preexisting sensitization to HLA alloantigens has been increasing. Sensitization prolongs duration to obtaining a donor and predicts poorer long-term allograft survival because of increased risk of cellular rejections. We investigated the effect of cyclophosphamide pulse therapy in sensitized cardiac allograft recipients.Pretransplant and posttransplant outcomes were compared between 88 cardiac allograft recipients at risk for sensitization and 26 sensitized recipients treated with intravenous cyclophosphamide pulse therapy together with intravenous immune globulin before transplant and as part of a cyclosporine-based triple immunosuppressive regimen after transplant. Preformed IgG anti-HLA antibodies predicted longer duration to transplantation, earlier cellular rejection, and 2.7-fold higher cumulative rejection frequency (P=0.002). Before transplant, cyclophosphamide reduced waiting time and mortality to levels in nonsensitized patients. After transplant, cyclophosphamide prevented induction of IgG anti-HLA class II antibodies and interleukin-2 receptor--positive T-cell outgrowth from biopsy sites (both P<0.01), prolonged the rejection-free interval (P=0.009), and reduced cumulative rejections to levels in nonsensitized patients (P=0.003). By multivariable analysis, the risk of rejection was 3.7-fold higher in patients treated with mycophenolate mofetil than patients treated with cyclophosphamide (P=0.019). There were no differences in infectious or other significant complications.Immunosuppression incorporating intravenous cyclophosphamide before and after transplantation is safe and highly effective in sensitized cardiac transplant recipients. When used after transplantation as part of triple immunosuppression, cyclophosphamide is superior to mycophenolate mofetil in reducing rejection. The mechanism may involve prevention of diversification of the recipient immune response to donor HLA class II molecules." @default.
• W2128421277 created "2016-06-24" @default.
• W2128421277 creator A5011932512 @default.
• W2128421277 creator A5013091913 @default.
• W2128421277 creator A5020761427 @default.
• W2128421277 creator A5043642364 @default.
• W2128421277 creator A5059965038 @default.
• W2128421277 creator A5062496285 @default.
• W2128421277 creator A5066324234 @default.
• W2128421277 creator A5074254969 @default.
• W2128421277 creator A5080446143 @default.
• W2128421277 date "2002-03-12" @default.
• W2128421277 modified "2023-09-30" @default.
• W2128421277 title "Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients" @default.
• W2128421277 cites W1966818078 @default.
• W2128421277 cites W1987107661 @default.
• W2128421277 cites W1988698783 @default.
• W2128421277 cites W2000620661 @default.
• W2128421277 cites W2002779814 @default.
• W2128421277 cites W2011309580 @default.
• W2128421277 cites W2018492373 @default.
• W2128421277 cites W2025090997 @default.
• W2128421277 cites W2039072312 @default.
• W2128421277 cites W2041205485 @default.
• W2128421277 cites W2052792640 @default.
• W2128421277 cites W2052927322 @default.
• W2128421277 cites W2053582855 @default.
• W2128421277 cites W2077907010 @default.
• W2128421277 cites W2092648747 @default.
• W2128421277 cites W2105298503 @default.
• W2128421277 cites W2168217071 @default.
• W2128421277 cites W2171309529 @default.
• W2128421277 cites W2325870812 @default.
• W2128421277 cites W4205848960 @default.
• W2128421277 cites W4242163166 @default.
• W2128421277 cites W4293241248 @default.
• W2128421277 doi "https://doi.org/10.1161/hc1002.105128" @default.
• W2128421277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11889016" @default.
• W2128421277 hasPublicationYear "2002" @default.
• W2128421277 type Work @default.
• W2128421277 sameAs 2128421277 @default.
• W2128421277 citedByCount "69" @default.
• W2128421277 countsByYear W21284212772012 @default.
• W2128421277 countsByYear W21284212772013 @default.
• W2128421277 countsByYear W21284212772014 @default.
• W2128421277 countsByYear W21284212772015 @default.
• W2128421277 countsByYear W21284212772016 @default.
• W2128421277 countsByYear W21284212772017 @default.
• W2128421277 countsByYear W21284212772018 @default.
• W2128421277 countsByYear W21284212772019 @default.
• W2128421277 countsByYear W21284212772020 @default.
• W2128421277 crossrefType "journal-article" @default.
• W2128421277 hasAuthorship W2128421277A5011932512 @default.
• W2128421277 hasAuthorship W2128421277A5013091913 @default.
• W2128421277 hasAuthorship W2128421277A5020761427 @default.
• W2128421277 hasAuthorship W2128421277A5043642364 @default.
• W2128421277 hasAuthorship W2128421277A5059965038 @default.
• W2128421277 hasAuthorship W2128421277A5062496285 @default.
• W2128421277 hasAuthorship W2128421277A5066324234 @default.
• W2128421277 hasAuthorship W2128421277A5074254969 @default.
• W2128421277 hasAuthorship W2128421277A5080446143 @default.
• W2128421277 hasBestOaLocation W21284212771 @default.
• W2128421277 hasConcept C126322002 @default.
• W2128421277 hasConcept C151032500 @default.
• W2128421277 hasConcept C203014093 @default.
• W2128421277 hasConcept C2776217527 @default.
• W2128421277 hasConcept C2776694085 @default.
• W2128421277 hasConcept C2776755627 @default.
• W2128421277 hasConcept C2778033501 @default.
• W2128421277 hasConcept C2780252810 @default.
• W2128421277 hasConcept C2911091166 @default.
• W2128421277 hasConcept C71924100 @default.
• W2128421277 hasConcept C90924648 @default.
• W2128421277 hasConceptScore W2128421277C126322002 @default.
• W2128421277 hasConceptScore W2128421277C151032500 @default.
• W2128421277 hasConceptScore W2128421277C203014093 @default.
• W2128421277 hasConceptScore W2128421277C2776217527 @default.
• W2128421277 hasConceptScore W2128421277C2776694085 @default.
• W2128421277 hasConceptScore W2128421277C2776755627 @default.
• W2128421277 hasConceptScore W2128421277C2778033501 @default.
• W2128421277 hasConceptScore W2128421277C2780252810 @default.
• W2128421277 hasConceptScore W2128421277C2911091166 @default.
• W2128421277 hasConceptScore W2128421277C71924100 @default.
• W2128421277 hasConceptScore W2128421277C90924648 @default.
• W2128421277 hasIssue "10" @default.
• W2128421277 hasLocation W21284212771 @default.
• W2128421277 hasLocation W21284212772 @default.
• W2128421277 hasOpenAccess W2128421277 @default.
• W2128421277 hasPrimaryLocation W21284212771 @default.
• W2128421277 hasRelatedWork W1992117911 @default.
• W2128421277 hasRelatedWork W2038585270 @default.
• W2128421277 hasRelatedWork W2128421277 @default.
• W2128421277 hasRelatedWork W2362001173 @default.
• W2128421277 hasRelatedWork W2428746395 @default.
• W2128421277 hasRelatedWork W2429914236 @default.
• W2128421277 hasRelatedWork W2441323929 @default.
• W2128421277 hasRelatedWork W3029187121 @default.
• W2128421277 hasRelatedWork W4324286885 @default.

• next